Printer Friendly

New England Biolabs Reveals Expanded NGS Sample Preparation Technology Pipeline at ASHG 2014.

IPSWICH, Mass., Oct. 16, 2014 /PRNewswire/ -- At the 64th Annual Meeting of the American Society of Human Genetics (ASHG) in San Diego, CA, New England Biolabs (NEB[sup.]) will present a workshop and a series of posters highlighting novel technologies that advance sample preparation for next-generation sequencing.

The workshop will include speakers from the Genome Sciences Centre, BC Cancer Agency and Yale University.

The workshop's presentations, to occur Monday October 20[sup.th] from 12:30 to 2:00PM in room 1A of the convention center, are as follows:

High Throughput Gel-free Library Construction from Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Specimens Yongjun Zhao, Genome Sciences Centre, BC Cancer Agency

Immune-Seq Technology Introduction Eileen Dimalanta, New England Biolabs, Inc.

High-throughput Immunoglobulin Sequencing Informatics: Insights into B cell Trafficking Patterns in Multiple Sclerosis Jason Vander Heiden, Yale University

Effective Ribosomal RNA Depletion from Multiple Sample Types Including FFPE RNA Fiona Stewart, New England Biolabs, Inc.

NEB will present six posters at the meeting, including methodologies in its development pipeline for FFPE DNA repair, target enrichment, immune repertoire sequencing and metatranscriptome enrichment. Additional topics include rRNA depletion from breast cancer FFPE samples and enrichment of microbiome DNA from a variety of sample types.

"As next-generation sequencing technologies advance and sequencing capacity increases, the need for effective sample preparation methods for a wider variety of applications, sample types and sample qualities increases. At New England Biolabs, we are committed to expanding the available range of high-performance sample preparation tools, and are pleased to highlight the breadth and depth of NEB's novel technology development at ASHG again this year," said Fiona Stewart, Product Marketing Manager, Next Generation Sequencing at NEB.

NEB Posters at ASHG

Recently Launched Technologies

* #3370T - Selective depletion of abundant RNAs to enable transcriptome analysis of low input and highly degraded RNA from FFPE breast cancer samples.

* #1699M - A method for selectively enriching microbial DNA from contaminating vertebrate host DNA.

Upcoming Technologies

* #1703T - Optimized DNA extraction and repair improves the yield and quality of sequencing libraries derived from FFPE samples.

Pipeline Technologies

* #1702M - Immune sequencing protocol for complete B-cell and T-cell repertoire sequencing.

* #2531S - A new approach to target capture for genetic testing: a novel DNA enrichment method for next-generation sequencing applied to clinically-relevant genes.

* #1683S - Development of a novel methodology for RNA-microbiome enrichment.

About New England Biolabs Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including molecular diagnostics development. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and seven subsidiaries located in Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs visit www.neb.com.

New England Biolabs[sup.], NEB[sup.] and NEBNext[sup.] are registered trademarks of New England Biolabs, Inc.

Logo - http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b

SOURCE New England Biolabs
COPYRIGHT 2014 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 16, 2014
Words:670
Previous Article:For Severe Obesity, Diets are No Cure.
Next Article:Regeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive Year.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters